Background {#Sec1}
==========

Fabry disease (FD - OMIM 301500) is a lysosomal storage disorder caused by pathogenic variants in the X-linked *GLA* gene (Xq22.1). *GLA* variants may produce α-Galactosidase A deficiency (α-Gal A; EC 3.2.1.22), which is required for degradation of glycosphingolipids. Deficiency in α-Gal A activity leads to storage of complex glycosphingolipids, mainly globotriaosylceramide (Gb3), inside of lysosomes in critical organs and tissues, impairing their functions and consequently resulting in a progressive multisystem disease, affecting people of all ethnic groups \[[@CR1], [@CR2]\].

FD presents a broad spectrum of heterogeneous clinical phenotypes, classified as classical and non-classical \[[@CR3]\]. In the classical disease, the suspicion of FD begins with peculiar signs and symptoms such as angiokeratomas, acroparesthesia, abdominal pain, recurring headache, and progressive loss of renal function, cardiomyopathy and central nervous system microangiopathy. Non-classical phenotype frequently is associated with damage in a single organ system, principally kidney, heart and brain \[[@CR4]\]. The clinical diagnosis of both phenotypes is challenging, since many of the main symptoms are common in other diseases \[[@CR5]\]. Indeed, the time between the first symptoms and the diagnosis can take more than ten years.

The FD male phenotypes are directly linked to the residual α-Gal A activity. The exact threshold value of FD pathogenicity is unknown. However, it is estimated that the cutoff for diagnosing FD is 30--35% of mean normal α-Gal A. Some *GLA* mutations cause a reduction of enzyme activity to less than 10--15% of the wild type and are considered pathogenic \[[@CR6]\]. However, others promoting a residual enzyme activity of at least 40% of the wild type protein can be considered as non-pathogenic \[[@CR7]\].

The enzymatic activity measured in leukocytes or fibroblasts is considered a gold standard for the diagnosis of FD in male patients; however, the sample required for this analysis may be a limiting factor \[[@CR8]\]. Thus, the analysis of α-Gal A activity in dried blood spot (DBS) samples has been shown to be a viable alternative, especially for screening in high-risk populations; however, confirmatory tests are required for the diagnosis \[[@CR9]\].

The FD molecular analysis is important for family segregation studies, allowing the early diagnosis of family members with pathogenic mutations, enabling the monitoring before the first symptoms and therefore promoting a better management of the symptoms of the disease in these individuals. More than 960 mutations have been reported as causing FD disease in the Human Gene Mutation Database (HGMD) \[[@CR10]\]; however, the pathogenicity of several exonic as well as, non-coding variants (NCV) is still controversial. We describe here an observational study based on biochemical analysis performed in DBS samples and genetic analysis in male individuals with suspicion of FD presenting characteristic clinical signs or belonging to high-risk populations, as patients with unexplained renal insufficiency, left ventricular hypertrophy or stroke without a known etiology. The results of the study show the profile of *GLA* variants in male Brazilian patients submitted to investigation of FD and the correlation between α-Gal A activity and genotype.

Methods {#Sec2}
=======

Patients and α-Gal A activity screening {#Sec3}
---------------------------------------

This study included 803 male patients with suspicion of FD after clinical investigation, as well as individuals with symptoms reported as non-specific, observed in FD patients (high-risk populations). All patients were screened by α-Gal A enzymatic activity, determined by the hydrolysis of the substrate 4-methylumbelliferyl-α-D-galactopyranoside in DBS samples by a fluorometric assay as described by Muller and colleagues \[[@CR11]\]. The cut-off value of enzymatic activity (compatible with FD diagnosis) used in this screening protocol was determined in healthy Brazilian volunteers \[[@CR11]\] and a pilot screening protocol in DBS samples from Brazilian patients of hemodialysis centers \[[@CR9]\].

DNA sequencing {#Sec4}
--------------

DNA was extracted from the blood sample using QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany), according to manufacturer's instructions. Alternatively, FTA Classic Cards (Whatman™) were used to facilitate the collection; DNA extraction was performed using Chelex 100 resin (Bio-Rad Laboratories, Hercules, CA, USA) according to instructions. The amplification and sequencing of the *GLA* regions were performed according to Varela and colleagues \[[@CR12]\]. We analyzed the seven exons, splicing sites and the regions flanking *GLA* exons. The introns in their entirety, as well as the promoter region, were not sequenced in this study.

Bioinformatic analysis {#Sec5}
----------------------

Data analysis was carried out using software Geneious® (Biomatters). Sequences were compared with the reference sequence (NCBI: NG_007119 (<http://www.ncbi.nih.gov>) and confirmed by sequencing the reverse strand. The variants were reviewed and annotated using dbSNP - Single-nucleotide polymorphism database and HGMD -- The Human Gene Mutation Database \[[@CR10]\]. Based on this analysis, the exonic mutations were divided into described pathogenic variants and variants of unknown significance (VUS). Mutations were correlated with the likely phenotype using the dbFGP - International Fabry Disease Genotype-Phenotype Database \[[@CR13]\], previous publications and functional characterization. GnomAD - Genome Aggregation Database \[[@CR14]\], 1000 Genomes Project Consortium \[[@CR15]\] and ABraOM: Online Archive of Brazilian Mutations \[[@CR16]\] were used to define the population frequency. The web-software Human Splicing finder \[[@CR17]\] was used to identify significant splicing motif alterations. Non-coding variants were also analyzed by TRAP - Transcript-inferred pathogenicity score \[[@CR18]\].

Non-coding variants analysis {#Sec6}
----------------------------

Complex non-coding haplotypes (NCH) were assessed according to their frequency in *The 1000 genomes database*. Briefly, 2504 multisample (phased variant call format - vcf) of the X-chromosome were filtered to rule out variants with two alleles (female sample). The remaining files that comprise 1233 samples of healthy male individuals were used as the control group. A combinatorial analysis was performed to determine the haplotypes. Complex haplotypes found in the 1000 genomes were compared to the patients to determine their frequency.

Statistical analysis {#Sec7}
--------------------

Correlation between enzyme activity and *GLA* sequencing were analyzed by one-way analyses of variance (ANOVA) with Turkey as *post-hoc*, performed using IBM SPSS® software (version 18). The level of significance was set at *p \< 0.05*.

Results {#Sec8}
=======

In this study, we analyzed patients with suspicion of FD with characteristic symptoms of the disease, as well as patients belonging to high-risk populations. Most of the patients presented renal disease and were screened in dialysis clinics (93%), while the other patients presented other symptoms that suggest FD. Details about these data are shown in Additional file [1](#MOESM2){ref-type="media"}: Table S1.

All individuals included were screened by α-Gal A enzymatic activity in DBS and presented low activity suggesting a possible FD diagnosis; however, other tests were requested to confirm. Of the total of males submitted to analysis, 783 were screened by enzymatic activity in DBS at the Laboratório de Erros Inatos do Metabolismo (LEIM -- UNIFESP), and presented enzyme activity below the cutoff (2.2 μmol/L/h). Other 20 patients included were screened by other laboratories, and the results are reported as positive to FD. These 20 patients presented exonic alterations; therefore, they were included in this study; however, they were not included in the statistical analysis. We performed the *GLA* sequencing to confirm the diagnosis.

*GLA* sequencing revealed 179 patients (22.3%) with mutations in the coding regions (exons), 335 patients had no variants in the analyzed regions (41.7%), and 289 patients (36%) had only NCV. We found 58 previously described variants in the *GLA* exons; 98 patients (12.2%) presented 50 pathogenic mutations and 81 patients (10%) presented eight VUS. The most frequent VUS was D313Y found in 38 index cases, followed by R118C found in 30 individuals. The most frequent pathogenic mutations were R356W and M290I, found in 17 and 10 patients, respectively. A list of described variants, the enzymatic activity, functional tests, and likely phenotype is shown in Table [1](#Tab1){ref-type="table"}. Table 1Described mutations in the *GLA* gene found in suspected FD patientsAminoacid change (NM_000169.2)Nucleotide changeExon LocationStop Codon PositionType of alterationNr. of familiesEnzymatic activity (μmol/L/h)dbSNPHGMDFunctional Characterization (%WT)Likely PhenotypeMeanRangePathogenic Mutations p.Q2\*c.4C\>T12Nonsense10.12rs869312313DMNo FCClassical (dbFGP) p.Gly11AlafsTer110c.32delG1110Deletion20.090 - 0.19rs1057516967DM1.8±1.4 \[[@CR19]\]Classical (dbFGP; HGMD) p.A15Ec.44C\>A1Missense10.06rs869312304DM0±0 \[[@CR42]\]Classical (dbFGP) p.A15Gc.44C\>G1Missense10.14No dbSNP IDDM19±0.7 \[[@CR36]\]Classical (dbFGP) p.G35Vc.104G\>A1Missense10.15No dbSNP IDDMNo FCClassical (HGMD) p.M42Ic.126G\>A1Missense10.17No dbSNP IDDMNo FCLikely Classical (dbFGP) / Classical (HGMD) p.W47\*c.140G\>A147Nonsense1+No dbSNP IDDMNo FCClassical (dbFGP) p.R49Cc.145C\>T1Missense10.31No dbSNP IDDM0±0 \[[@CR19]\]Classical (dbFGP; HGMD) p.R49Gc.145C\>G1Missense10No dbSNP IDDM0±0 \[[@CR19]\]Classical (dbFGP) p.R49Pc.146G\>C1Missense10.25rs398123205DMNo FCClassical (dbFGP; HGMD) p.C52\*c.156C\>A152Nonsense10.41No dbSNP IDDMNo FCClassical (dbFGP; HGMD) p.F69Lc.207C\>A2Missense1+No dbSNP IDDMNo FCMild/Late-onset - cardiac variant (dbFGP; HGMD) p.W81\*c.242G\>A281Nonsense1+rs398123208DMNo FCClassical (dbFGP; HGMD) p.C94Yc.281G\>A2Missense20rs113173389DM0±0 \[[@CR19]\]Classical (dbFGP; HGMD) p.R100Kc.299G\>A2Missense1+rs869312273DM0±0 \[[@CR20]\]Classical (dbFGP; HGMD) p.R112Cc.334C\>T2Missense50.250 - 1.25rs104894834DM0±0 \[[@CR20], [@CR42]\]Classical (dbFGP; HGMD) p.R112Hc.335G\>A2Missense30.170.03 - 0.28rs869312273DM0±0 \[[@CR20]\]; 1.6±0.6 \[[@CR42]\]Mild proteinuria -Later-onset (dbFGP; HGMD) p.F113Lc.337T\>C2Missense10.27rs869312142DM17.3±3.6 \[[@CR20]\]; 18.3±0.8 \[[@CR36]\]Later onset (dbFGP); Cardiac variant (HGMD) p.G132Ec.395G\>A3Missense10.01No dbSNP IDDM0±0 \[[@CR42]\]Classical (dbFGP) p.C142Rc.424T\>C3Missense200 - 0.01No dbSNP IDDM0±0 \[[@CR20], [@CR42]\]Classical (dbFGP; HGMD) p.A156Dc.467C\>A3Missense20.160 - 0.33rs869312307DM0±0 \[[@CR42]\]Classical (dbFGP) p.C172Yc.515G\>A3Missense10.03rs869312318DM0±0 \[[@CR42]\]Classical (dbFGP) p.M187Tc.560T\>C4Missense1+rs869312342DM0±0 \[[@CR42]\]Classical (dbFGP; HGMD) p.C202Yc.605G\>A4Missense1+rs869312344DM0±0 \[[@CR43]\]Classical (dbFGP; HGMD) p.I198Tc.593T\>C4Missense10.15rs727503950DM38.7±3.1 \[[@CR43]\]Later onset (dbFGP) p.W204\*c.611G\>A4204Nonsense10.7rs869312346DMNo FCClassical (dbFGP) p.N215Sc.644A\>G5Missense20.340.22 - 0.47rs28935197DM15.6±1.0 \[[@CR36]\] /15.7±2.4 \[[@CR20]\] / 39.5±1.5 \[[@CR43]\]Later onset (dbFGP) p.R220\*c.658C\>T5220Nonsense10.06rs727503949DM0±0 \[[@CR43]\]Classical (dbFGP) p.W226\*c.677G\>A5226Nonsense10.48rs398123219DMNo FCClassical (dbFGP) p.R227\*c.679C\>T5227Nonsense30.080.06 - 0.11rs104894841DMNo FCClassical (dbFGP; HGMD) p.R227Qc.680G\>A5Missense10rs104894840DM0±0 \[[@CR20], [@CR42]\]Classical (dbFGP; HGMD) p.Lys240Glufs\*9c.718_719delAA5248Deletion10.01No dbSNP IDDMNo FCClassical (dbFGP) p.M267Ic.801G\>A5Missense10.17rs869312408DMNo FCClassical (dbFGP; HGMD) p.V269Mc.805G\>A6Missense1+rs869312427DM0±0 \[[@CR43]\]Classical dbFGP; HGMD) p.V269Ac.806T\>C6Missense10.41rs28935488DM9.0±1.4 \[[@CR42]\]Classical (dbFGP; HGMD) p.T282Ic.845C\>T6Missense10.05No dbSNP IDDM5.0±0.5 \[[@CR42]\] / 5.2±0.2 \[[@CR36]\]Classical (dbFGP) p.M290Ic.870G\>A6Missense100.310 - 0.60rs869312438DM39±1.8 \[[@CR42]\]Later onset (dbFGP) - Classical (HGMD) p.A292Vc.875C\>T6Missense10.54No dbSNP IDDMNo FCClassical (dbFGP) p.P293Sc.877C\>T6Missense10.10rs869312440DMNo FCClassical (dbFGP) p.R301Gc.901C\>G6Missense10,34rs398123224DM19±4.1 \[[@CR42]\]VUS (dbFGP) p.R301\*c.901C\>T6301Nonsense20.060.01 -- 0.11rs398123224DMNo FCClassical (dbFGP) - Kidney disease (HGMD) p.Gln333Glufs\*14c.996_999delACAG6346Deletion21.84rs398123229DMNo FCClassical (dbFGP; HGMD) p.R342Qc.1025G\>A7Missense40.070 -0.14rs28935493DM0±0 \[[@CR20], [@CR42]\]Classical (dbFGP) p.Ser345Argfs\*29c.1033_1034delTC7373Deletion20.21rs398123198DMNo FCClassical (dbFGP) p.W349\*c.1046G\>A7349Nonsense10,45No dbSNP IDDMNo FCClassical (dbFGP) p.R356Wc.1066C\>T7Missense170.470.19 - 1.62rs104894827DM16.9±2.3 \[[@CR42]\]Later onset (dbFGP) p.R363Hc.1088G\>A7Missense30.430.13 - 0.72rs111422676DM31.9±2.9 \[[@CR42]\]Later onset (dbFGP) - Renal presentation (HGMD) p.Y365\*c.1095T\>A7365Nonsense30.060 - 0.13rs104894849DMNo FCClassical (dbFGP) p.W399\*c.1196G\>A7399Nonsense1+No dbSNP IDDM2% \[[@CR21]\]Classical (dbFGP; HGMD) p.Thr412Serfs\*?c.1235_1236delCT7late termination codonDeletion10rs797044777DMNo FCClassical (dbFGP; HGMD)Variants of Unknown Significance p.E66Qc.196G\>C2Missense1+rs104894833DFP52.0±1.3 \[[@CR36]\]Benign (dbFGP) p.R118Cc.352C\>T2Missense301.681.15 - 2.10rs148158093DM24.0±1.3 \[[@CR36]\]Benign (dbFGP); Cardiac variant (HGMD) p.A143Tc.427G\>A3Missense81.040.58 - 1.86rs104894845DM31.3±5.6 \[[@CR42]\]Benign (dbFGP) p.R220Qc.659G\>A5Missense11.17rs727503949DM?104±11.3 \[[@CR42]\]Likely bening (dbFGP) p.N228Sc.683A\>G5Missense12.03rs869312152DM59.5±9.8 \[[@CR43]\] / 124.5±4.1 \[[@CR36]\]Likely benign (dbFGP) p.D313Yc.937G\>T6Missense381.650.72 - 2.10rs28935490DM?83.9±21.1 \[[@CR42]\]Benign (dbFGP) p.R356Qc.1067G\>A7Missense10.9rs869312163DM89.1±5.0 \[[@CR42]\] / 36.1±1.5 \[[@CR36]\]Later onset (dbFGP) p.A368Tc.1102G\>A7Missense11.691.69rs144994244DM?103.7±33.6 \[[@CR42]\]Benign (dbFGP)*F* Female, *M* Male, *No FC* No functional characterization, *NA* Not Applicable, *VUS* Variant of Unknown Significance, *DM* Disease Causing Mutation, *DM?* Disease Causing Mutation?, *DFP* disease-associated polymorphism with supporting functional evidence, dbFGP (International Fabry Disease Genotype-Phenotype Database <http://dbfgp.org/dbFgp/fabry/>); DBS enzymatic activity applicable only for male: for samples screened by LEIM-UNIFESP the result is show as μmol/L/h; for samples screened by other laboratories, the result is show as + (positive)

Non-coding variants {#Sec9}
-------------------

Two hundred and eighty nine patients presented only NCV in the *GLA*. A list of all NCV, the population frequency and in silico predictor is shown in Additional file [2](#MOESM1){ref-type="media"}: Table S2. Seven NCV form nine NCH. To analyze the frequency of NCH, we used data from *The 1000 Genomes* (only male) as the control group. Except for the haplotype c.-10C \> T / c.370-77_370-81delCAGCC / c.640-16A \> G / c.802-67G \> A / c.1000-22C \> T, found only in one patient of this study, all other haplotypes were also found in the control group. The results are shown in Table [2](#Tab2){ref-type="table"}. Table 2Complex non-coding haplotypes found in male patients with suspicion of FD and population frequency in *The 1000 Genomes* ProjectDNA RegionVariant / HaplotypeEnzyme Activity (μmol/L/h)PatientsThe 1000 GenomesMeanRange*N* = 624%*N* = 1233%Without *GLA* variantsWithout intronic variants1.760.09--2.233553.770557.1Variant 15'UTRc.-30G \> A1.60--10.1620.16Variant 25'UTRc.-10C \> T1.721.13--2.1060.7410.08Variant 3Intron 1c.194 + 17A \> G2.11--10.16282.27Variant 4Intron 6c.1000-22C \> T1.760.60--2.19589.2914711,92Haplotype 15'UTR / intron 6c.-12G \> A / c.1000-22C \> T1.110.80--1.4220.3210.08Haplotype 25'UTR / intron4 / intron 6c.-12G \> A / c.639 + 68 A \> G / c.1000-22C \> T1.640.90--2.20233.6812710.3Haplotype 35'UTR / intron 2 / intron 4c.-12G \> A / c.370-77_370-81delCAGCC / c.640-16A \> G----0010.08Haplotype 45'UTR / intron 2c.-10C \> T / c.370-77_370-81delCAGCC----0010.08Haplotype 55'UTR / intron 6c.-10C \> T / c.1000-22C \> T1.810.17--2.20599.45312.51Haplotype 65'UTR / intron 4 / intron 6c.-10C \> T / c.640-16A \> G / c.1000-22C \> T2.07--10.1640.32Haplotype 75'UTR / intron 2 / intron 4 / intron 6c.-10C \> T / c.370-77_370-81delCAGCC / c.640-16A \> G / c.1000-22C \> T1.720.70--2.2010717.1412510.14Haplotype 85'UTR / intron 2 / intron 4 / intron 5 / intron 6c.-10C \> T / c.370-77_370-81delCAGCC / c.640-16A \> G / c.802-67G \> A / c.1000-22C \> T2.07--10.1600Haplotype 9intron 2 / intron 4 / intron 6c.370-77_370-81delCAGCC / c.640-16A \> G / c.1000-22C \> T1.680.77--2.20304.8604.87

The most frequent haplotype is formed by the four variants c.-10C \> T, c.370-77_370-81delCAGCC, c.640-16A \> G and c.1000-22C \> T. It was found in 107 (17.1%) patients and 125 individuals (10.1%) in the control group. The haplotype formed by c.-10C \> T and c.1000-22C \> T occurred with a frequency almost fourfold higher in patients with suspected FD than in the control group. The other haplotypes present similar frequency in patients and controls.

Enzymatic profile {#Sec10}
-----------------

The correlation between the *GLA* variants and the α-Gal A activity levels were evaluated to estimate the impact of the variants in the enzyme in male patients screened by enzymatic activity in LEIM and presenting less than 2.2 μmol/L/h (*N* = 783). The patients were divided into groups according to the classification of their mutations. Figure [1](#Fig1){ref-type="fig"}a shows the distribution of enzymatic activity per patient in each group. Fig. 1Enzymatic profile of *GLA* genotypes. **(a)** Scatter plot of the α-Gal A activity distribution in males with FD suspicion in different groups. The figure shows that most males with VUS, NCV and without variants present α-Gal A levels above 1 μmol/L/h, while patients with pathogenic variants presented α-Gal A levels lower than 1 μmol/L/h. Some outliers were found in each group. Three patients with pathogenic variants presented enzyme activity above 1 μmol/L/h, while twenty-four patients with only non-coding variants, twenty without variants and seven with VUS, being four with A143T, two with D313Y and one with R356Q, presented enzyme activity below 1 μmol/L/h. **(b)** Correlation analysis between α-Gal A level in DBS and *GLA* genotypes. The graphic shows the mean enzymatic activity detected in males in all the *GLA* variant groups. The data are expressed as mean ± S.E.M. \*\**P \< 0.001* known pathogenic mutation (0.27 μmol/L/h ± 0.03, *N* = 83) versus VUS (1.58 μmol/L/h ± 0.04, *N* = 76), non-coding variants (1.73 μmol/L/h ± 0.02, *N* = 289) and the group without variants in *GLA* (1.77 μmol/L/h ± 0.02, *N* = 335); \**P = 0.013* VUS versus NCV and \**P = 0.01* VUS versus patients without variants

Males with variants previously described as pathogenic had significantly lower enzymatic activity when compared with the other groups (mean 0.27 μmol/L/h, *p \< 0.001*). The VUS showed a significant decrease of residual α-Gal A levels (mean 1.58 μmol/L/h) when compared with the group without variants (mean 1.73 μmol/L/h; *p = 0.001*) and the NCV group (mean 1.77 μmol/L/h; *p = 0.013*). There was no difference in α-Gal A levels between the group without mutation in *GLA* and the group with NCV (*p = 0.64*). The results are shown in Fig. [1](#Fig1){ref-type="fig"}b.

Discussion {#Sec11}
==========

*GLA* sequencing allows the identification of genetic mutations associated with FD and the detection of these variants is fundamental to support the diagnosis. Main FD symptoms are shared with other diseases, making the diagnosis based on such symptoms challenging. The FD clinical suspicion starts with characteristic signs and symptoms that appear over the years, promoting a delay of at least 10 years to diagnose a patient \[[@CR5]\]. Therefore, in the last two decades, the number of screening studies in high-risk and in newborn population has increased.

The α-Gal A activity in DBS has been used for screening purposes and should be followed by enzymatic activity in leukocytes or DNA sequencing to confirm the diagnosis \[[@CR9]\]. The efficacy of the applicability of enzymatic activity in DBS as an alternative screening test has been reported \[[@CR8], [@CR22]--[@CR24]\]. Fuller and colleagues \[[@CR25]\] tested DBS enzyme activity assay in FD hemizygous patients and found a clearly decrease in α-Gal A activity when compared with a control population. A comparison between the enzymatic activity assay in DBS versus leukocytes, conducted in male patients with known FD demonstrated that both assays were equally good \[[@CR26]\]. Here, we analyzed by DNA sequencing 803 male individuals with low enzymatic activity in DBS. All patients presented suspicion of FD after clinical investigation or showed undefined symptoms as those observed in FD patients. However, a limitation of this study was the lack of detailed information on the patient's clinic.

According to Van der Tol and coworkers \[[@CR27]\], the prevalence of *GLA* variants in a high-risk population is 0.12%, when considered only pathogenic variants; when VUS are included, this frequency increases to 0.62%. FD is screened in dialysis centers as one possible cause of end-stage renal disease. Not surprisingly, nephrologists referred most patients included in this study, and they were predominantly followed in dialysis services. We performed the DNA sequencing only in individuals with low enzymatic activity screened by DBS assay. Interestingly, we found a high frequency of variants in our patients: 22.2% of individuals with enzymatic activity lower than 2.2 μmol/L/h presented *GLA* variants. Of these, 12.2% present pathogenic variants and 10% VUS. The numbers showed here do not reflect the Van der Tol data, which could be due to the fact that here we included only patients with low activity and not those with activity within the normal range.

In addition to exonic mutations, NCV were also detected. The comparison between patients and controls showed that seven NCV were observed in more than 1% of the control population, being considered as polymorphisms. Other two variants were extremely rare or were not found in any databank consulted. Despite rare, in silico pathogenic analysis did not consider any of the NCV found in this study as damaging.

Nine different NCH were found. Seven of them presented similar frequency in patients and control group. Our results are in agreement with the findings of Ferri and colleagues \[[@CR28]\], who found seven different *GLA* haplotypes in control males, indicating that these NCH, per se, are not involved in the development of FD manifestations. However, the haplotypes 5 and 7 present higher frequency in patients when compared with controls. The haplotype 7 was already described in patients with FD suspicion \[[@CR29], [@CR30]\]. Both haplotypes contain the variant c.-10C \> T, described as causing a decrease of approximately 25% of the α-Gal A activity \[[@CR31]\]. As described by Oliveira and colleagues \[[@CR31]\], we also found approximately 4-fold higher frequency of this variant in our patients when compared to general population. In our study, these haplotypes were found in males with enzymatic activity below the cut-off (\~ 1.73 μmol/L/h), equivalent to a decrease of 21% of α-Gal A activity, indicating that c.-10C \> T may cause this decrease. Residual enzyme activity of about 40% of the mean normal level can be considered enough to degrade the substrate, not promoting Gb3 accumulation \[[@CR6], [@CR7]\]. However, recent studies have demonstrated that, despite not altering the enzyme structure, patients with the haplotype 7 had significant levels of Gb3 accumulation when compared with controls \[[@CR32], [@CR33]\]. Gervas-Arruga and colleagues \[[@CR32]\] suggest that in patients with this NCH, environmental factors, as a pro-inflammatory state, in addition to the accumulation of Gb3 may influence the symptoms.

An important finding of this study was the different levels of residual activity in DBS samples among the genotypes. By comparing the mean enzymatic activity, we have observed that described pathogenic variants showed significantly lower mean enzymatic activity, equivalent to 12% of the value found in healthy individuals. On the other hand, VUS including D313Y, R118C, and A143T, considered by many researchers as not causing FD \[[@CR34]--[@CR39]\] and by others as pathogenic \[[@CR40], [@CR41]\], presented higher enzymatic activity in comparison to individuals with pathogenic mutations. In contrast, patients carrying VUS present enzymatic levels statistically lower when compared to patients with NCV or patients without mutations in *GLA*. In fact, in in vitro experiments, the VUS found in this study showed a decreased α-Gal A activity, exception for R220Q and A368T, which have α-Gal A activity similar to that of the wild type \[[@CR36], [@CR42]\]. However, data from different groups showed that this decrease is not sufficient to promote glycosphingolipid accumulation, which would lead to disease \[[@CR37], [@CR42]\]. Although enzymatic activity of VUS were statistically different from NCH and patients without variants, these genotypes present values higher than 70% of the residual activity found in health population. It is already described that activity above 40% of the level found in health population is enough to degrade Gb3, therefore our results indicate that these genotypes are not compatible with FD. However, further studies are necessary to rule out FD in these patients.

In summary, in this study we sequenced a large group of male patients with suspicion of FD presenting enzymatic activity below the cutoff (2.2 μmol/L/h) and showed that pathogenic variants lead to a low residual enzymatic activity, while VUS, NCV and patients without *GLA* variants, lead to approximately 70% of the normal activity, indicating a possible non-pathogenicity. In addition, we showed, by bioinformatics correlation, that the frequency of most haplotypes formed by non-coding variants in the healthy population is similar to the frequency found in patients with suspicion of FD, and therefore, the haplotypes per se, do not correlate with FD. However, in the haplotypes most frequently observed in patients group, although presenting high levels of residual activity when compared with the pathogenic variants, other studies are necessary to discard the FD diagnosis. Moreover, the correlation between DBS enzyme activity and *GLA* variants revealed that this screening method is useful for diagnosing previously described mutations. However, when the patient presents VUS or NCH, although our study indicates a possible non-pathogenicity, the diagnosis may not be conclusive and other tools may be necessary to confirm or discard the disease. Indeed, new specific studies are necessary to correlate these genotypes with FD.

Conclusions {#Sec12}
===========

In this observational study, we identified 98 patients with described pathogenic variants in *GLA* gene, confirming FD diagnosis. In these patients, the enzymatic activity in DBS samples was below 0.3 μmol/L/h, equivalent to 12% of the residual activity of healthy individuals; significantly lower when compared with the other genotypes. On the other hand, 80 patients presented only VUS, and in these cases FD diagnosis was not confirmed, as well as in patients with NCV. Our study indicates a possible non-pathogenic potential of these latter genotypes by population frequency of haplotypes and correlation between the enzymatic phenotype in DBS samples and *GLA* variants. These findings highlight the importance of determining α-Gal A activity by DBS in the diagnosis of FD, considered as the only available tool for this purpose in many countries.

Supplementary information
=========================

 {#Sec13}
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ABraOM

:   Online Archive of Brazilian Mutations

dbFGP

:   International Fabry Disease Genotype -- Phenotype Database

DBS

:   Dried Blood Spot

FD

:   Fabry Disease

Gb3

:   Globotriaosylceramide

GnomAD

:   Genome Aggregation Database

HGMD

:   Human Gene Mutation Database

NCH

:   Non-coding haplotypes

NCV

:   Non-coding variants

TRAP

:   Transcript-inferred pathogenicity score

VCF

:   Variant call format

VUS

:   Variants of unknown significance

α-GalA

:   α-Galalactosidase A
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